Trials / Recruiting
RecruitingNCT06371157
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 469 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK104 | intravenous |
| DRUG | Lenvatinib | oral |
| PROCEDURE | TACE | TACE (chemo and embolic agent injection into the hepatic artery) |
| OTHER | Placebo for AK104 | intravenous |
| OTHER | Placebo for Lenvatinib | oral |
Timeline
- Start date
- 2024-08-02
- Primary completion
- 2025-10-25
- Completion
- 2026-05-23
- First posted
- 2024-04-17
- Last updated
- 2025-03-12
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06371157. Inclusion in this directory is not an endorsement.